1. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients;Krenning;Eur J Nucl Med,1993
2. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide: a case history;Krenning;Ann N Y Acad Sci,1994
3. FDA letter of approval for LUTATHERA® Accessed January 27, 2024 Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208700Orig1s000ltr.pdf
4. Authorization details for Lutathera® in Europe. Accessed January 27, 2024; Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera#authorisation-details-section
5. Saul Hertz: the discovery of the medical uses of radioiodine;World J Nucl Med,2019